Lupus & antiphospholipid syndrome
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control study
Authors' conclusion
Urine sTREM-1 might serve as a potential biomarker of active renal SLE.
Study context
- Population
- Consecutive adult patients with systemic lupus erythematosus (SLE) attending a tertiary lupus clinic, 2016–2018 (mean age 41.5+2.9 years, 85% female)
- Participants
- 59 SLE patients
- Comparison
- Plasma and urine sTREM-1 levels across active renal lupus (ARL), ANL, inactive lupus (IL) and healthy controls
- ARLn = 15
- ANLn = 14
- ILn = 30
- Outcome
- Plasma and urine sTREM-1 levels (ELISA) as biomarker of lupus nephritis (LN) and extra-renal SLE
Methodological detailsprospective, single tertiary lupus clinic, matched healthy controls
- Prospective
- Single tertiary lupus clinic
- Matched healthy controls
Main finding
As reported in the abstract
- Plasma sTREM-1 level highest in ANL (p=0.0085)
- Neither plasma nor urine sTREM-1 associated with non-renal SLE features
- SLE cohort vs Healthy controls: P = 0.0249
- ARL vs ANL and IL: P = 0.0044
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| SLEDAI-2K, renal-SLEDAI and urine protein/creatinine ratioARL vs ANL and IL · higher in ARL | P = 0.0001 for all |
Spearman correlations of urine sTREM-1 (not plasma)
- Renal-SLEDAI score, r (p=0.018)
- 0.34
- Serum C3, r (p=0.0027)
- −0.42
- Serum C4, r (p=0.056)
- −0.28
- Proteinuria (UPCR), r (p=0.0305)
- 0.32
Original publication
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control study. Clin Exp Rheumatol. Published 10 April 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →